Oncogenic Pathway Profiling in Ovarian Cancer
Author Information
Author(s): Trinh Xuan Bich, Tjalma Wiebren A. A., Dirix Luc Y., Vermeulen Peter B., Peeters Dieter J., Bachvarov Dimcho, Plante Marie, Berns Els M., Helleman Jozien, Van Laere Steven J., van Dam Peter A.
Primary Institution: Translational Cancer Research Unit, St Augustinus GZA Hospitals, Antwerp, Belgium
Hypothesis
The study aims to analyze oncogenic pathways in ovarian cancer and their relation with clinical outcomes.
Conclusion
Increased activation of certain oncogenic pathways is significantly associated with more favorable clinical outcomes in advanced serous ovarian tumors.
Supporting Evidence
- Increased β-Catenin activation was associated with more favorable clinical outcomes.
- PR and RAS activation scores were linked to survival outcomes.
- Unexpectedly, WHR, GGI, and IGS scores were higher in chemosensitive tumors.
Takeaway
This study looked at how certain pathways in ovarian cancer can help predict how well patients will do. They found that some pathways are linked to better outcomes.
Methodology
A meta-analysis of 6 gene expression datasets was performed to analyze oncogenic pathway activation scores and their correlation with survival outcomes.
Potential Biases
The selection of datasets may introduce biases related to treatment and histology.
Limitations
The study's findings may be confounded by the predictive versus prognostic value of the pathways analyzed.
Participant Demographics
Patients included were those with advanced serous papillary ovarian carcinoma.
Statistical Information
P-Value
p=0.0009; p=0.002; p=0.004; p=0.005; p=0.003; p=0.05
Confidence Interval
95%CI [0.62–0.88]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website